Advertisement

1147-C Urolithin-A promotes CD8+ T cell-mediated cancer immunosurveillance via FOXO1 activation

August, 08, 2024 | Select Oncology Journal Articles

Background

CD8+ T cells are vital for their protective roles against pathogens and cancer. Aging and cancer are known to promote defecst in the quality and quantity of functional naïve T cells thus lowering immune surveillance. Interventions aimed to improve and to sustain the quality of naïve T cells are needed for cancer immunoprevention. We recently showed that the mitochondrial modulator mitophagy inducer Urolithin-A (UroA) improves immune system function by ameliorating the mitochondrial pool in Hematopoietic Stem Cells (HSCs).1 However, the direct contribution of UroA on the homeostasis and functionality of CD8+ T cells has not been investigated.

Methods

We adopted in vitro assays and in vivo tumor models to investigate the contribution of UroA in improving CD8+T quality and functionality.

Results

Our current study demonstrates that orally supplemented UroA reduces tumor progression in mice in a CD8+ T-cell dependent manner. We show that preexposure to UroA enriched diet is sufficient to induce a robust antitumor response identifying UroA as an immunosurveillance agent. Notably, UroA supplementation promotes expansion of naïve CD8+ T cells in vivo. Furthermore, UroA improves cytokine production, mitochondrial activity in CD8+ T cells and promotes memory differentiation in vitro. Interestingly, we reveal the transcription factor FOXO1 as a non-mitochondrial target of UroA in CD8+ T indicating a novel mitophagy-independent UroA mode of action. Furthermore, we have optimized dosage and timing of UroA supplementation in vitro for long expansion of CD8+T cells with a superior anti-tumor in the context of adoptive T cell therapy (ACT).

Conclusions

Overall, our finding provide preclinical evidence supporting the therapeutic function of UroA as novel immunomodulator to improve immunosurveillance.

Reference

  • Mukul Girotra, Yi-Hsuan Chiang, Melanie Charmoy, Pierpaolo Ginefra, Helen Carrasco Hope, Charles Bataclan, Yi-Ru Yu, Frederica Schyrr, Fabien Franco, Hartmut Geiger, Stephane Cherix, Ping-Chih Ho, Olaia Naveiras, Johan Auwerx, Werner Held, Nicola Vannini. Nature Aging.

  • For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –

    Advertisement

    LATEST

    Advertisement

    Sign up for our emails

    Trusted insights straight to your inbox and get the latest updates from OncWeekly

    Privacy Policy